Risk factors for osteonecrosis of the jaws: A case-control study from the CONDOR dental PBRN

Journal of Dental Research

Volumn 90, Issue 4, 2011, Pages 439-444

  Barasch, A ^a   Cunha Cruz, J ^b   Curro, F A ^c   Hujoel, P ^b   Sung, A H ^d   Vena, D ^e   Voinea Griffin, A E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d YALE UNIVERSITY   (United States)

^e EMMES CORPORATION   (United States)

Author keywords

bisphosphonates; jaws; osteonecrosis; risk factors

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE; ANEMIA; BONE NECROSIS; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; GINGIVA BLEEDING; HUMAN; INCOME; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PARTICIPATORY RESEARCH; RADIOTHERAPY; RISK FACTOR; SMOKING; SUPPURATION; TIME; TOOTH EXTRACTION;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANEMIA; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; CHRONIC DISEASE; COMMUNITY-BASED PARTICIPATORY RESEARCH; DIABETES COMPLICATIONS; DIPHOSPHONATES; EDUCATIONAL STATUS; FEMALE; GINGIVAL HEMORRHAGE; HUMANS; INCOME; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; NEOPLASMS; OSTEONECROSIS; OSTEOPOROSIS; RADIOTHERAPY; RISK FACTORS; SMOKING; SUPPURATION; TIME FACTORS; TOOTH EXTRACTION;

EID: 79954610809     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034510397196     Document Type: Conference Paper

References (31)

1. Almazrooa SA, Woo SB (2009). Bisphosphonate and nonbisphosphonateassociated osteonecrosis of the jaw. A review J Am Dent Assoc 140: 864-875.
2. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., Rapoport A., et al. (2006). Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: 945-952. (Pubitemid 46638849)
3. Bamias A., Kastritis E., Bamia C., Moulopoulos LA, Melakopoulos I., Bozas G., et al. (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587. (Pubitemid 46211499)
4. Berenson JR, Lichtenstein A., Porter L., Dimopoulos MA, Bordoni R., George S., et al. (1996). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493. (Pubitemid 26067736)
5. Berenson JR, Hillner BE, Kyle RA, Anderson K., Lipton A., Yee GC, et al. (2002). American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20: 3719-3736. (Pubitemid 34983232)
6. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S., Quandt SA, et al. (2006). Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. J Am Med Assoc 296: 2927-2938. (Pubitemid 46021497)
7. Body JJ (2009). Bisphosphonates for care and cure. Eur J Cancer 45 (Suppl1). 396-397.
8. Boonyapakorn T., Schirmer I., Reichart PA, Sturm I., Massenkeil G., et al. (2008). Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44: 857-869.
9. Calvo-Alen J., McGwin G., Toloza S., Fernandez M., Roseman JM, Bastian HM, et al. (2006). Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 65: 785-790. (Pubitemid 43799179)
10. D'Agostino RB (1998). Propensity score methods for bias reduction for the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281.
11. Devogelaer JP (2000). Treatment of bone disease with bisphosphonates, excluding osteoporosis. Cur Opin Rheumatol 12: 331-335.
12. Enwonwu CO, Falkler WA, Idigbe EO (2000). Oro-facial gangrene (noma/ cancrum oris): pathogenetic mechanisms. Crit Rev Oral Biol Med 11: 159-171. (Pubitemid 30481378)
13. Hillner BE, Ingle JN, Chlebowski RT, Gralow J., Yee GC, Janjan NA, et al. (2003). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042-4057 ; erratum in J Clin Oncol 22: 1351, 2004. (Pubitemid 46606220)
14. Hortobagyi GN, Theriault RL, Porter L. (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785-1791. (Pubitemid 26412396)
15. Jereczek-Fossa BA, Orecchia R. (2002). Radiotherapy-induced mandibular complications. Cancer Treat Rev 28: 65-74.
16. Khamaisi M., Regev E., Yarom N., Avni B., Leitersdorf E., Raz I., et al. (2007). Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92: 1172-1175. (Pubitemid 46465699)
17. Khosla S., Burr D., Cauley J., Dempster DW, Ebeling PR, Felsenberg D., et al. (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479-1491. (Pubitemid 351229318)
18. Marx RE, Sawatari Y., Fortin M., Broumand V., et al. (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575. (Pubitemid 41525412)
19. Najm WI, Reinsch S., Hoehler F., Tobis JS, Harvey PW (2004). S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord 5: 6.
20. Reddy R., Daftary MN, Delapenha R., Dutta A., Oliver J., Frederick W. (2005). Avascular necrosis and protease inhibitors. J Natl Med Assoc 97: 1543-1546. (Pubitemid 41642533)
21. Robin M., Guardiola P., Devergie A., Yeshurun M., Shapiro S., Esperou H., et al. (2005). A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 19: 1613-1620. (Pubitemid 43090406)
22. Ross JR, Saunders Y., Edmonds PM, Patel S., Broadley KE, Johnston SR, et al. (2003). Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327: 469.
23. Ruggiero SL, Mehrotra B., Rosenberg TJ, Engroff SL (2004). Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534. (Pubitemid 38542516)
24. Schwartz O., Kvorning SA (1982). Tooth exfoliation, osteonecrosis of the jaw and neuralgia following herpes zoster of the trigeminal nerve. Int J Oral Surg 11: 364-371. (Pubitemid 13162383)
25. Silverman SL, Maricic M. (2007). Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 37: 1-12. (Pubitemid 47087884)
26. Stafford RS, Drieling RL, Hersh AL (2004). National trends in osteoporosis visits and osteoporosis treatment. Arch Intern Med 164: 1525-1530. (Pubitemid 38970472)
27. Sun W., Li ZR, Shi ZC, Zhang NF, Zhang YC (2006). Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. Int Orthop 30: 143-146. (Pubitemid 44324066)
28. Talamo G., Angtuaco E., Walker RC, Dong L., Miceli MH, Zangari M., et al. (2005). Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol 23: 5217-5223. (Pubitemid 46224032)
29. Tarassoff P., Csermak K. (2003). Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61: 1238-1239. (Pubitemid 37193509)
30. Wang J., Goodger NM, Pogrel MA (2003). Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61: 1104-1107. (Pubitemid 37064708)
31. Woo SB, Hellstein JW, Kalmar JR (2006). Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761 ; erratum in Ann Intern Med 145: 235, 2006. (Pubitemid 46780635)